Exercise News and Research

Latest Exercise News and Research

NeoMed invests in CytoCore

CytoCore Inc., the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, announced today that NeoMed has made an investment in CytoCore Inc.

11 Mar 2010

National Public Health Agenda for Osteoarthritis launched with assistance from UNC

Betty Isaacs of Boone, N.C., knows all about the chronic pain of osteoarthritis and the impact it has on her life. "The pain in my knee was so bad, I would just sit around," Isaacs said.

11 Mar 2010

StemCells reports net loss of $5.23M for fourth-quarter fiscal 2009

StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.

11 Mar 2010

Columbia Laboratories' fourth-quarter 2009 net revenues up 21%

Columbia Laboratories, Inc. today reported financial results of the three- and twelve-months periods ended December 31, 2009.

11 Mar 2010

Senetek closes Security Purchase Agreement with DMRJ

Senetek PLC today announced the closing of a Security Purchase Agreement, a Note and a Warrant Purchase Agreement DMRJ Group, LLC on March 4, 2010. DMRJ Group, LLC is a Delaware limited liability company affiliated with Platinum Partners Value Arbitrage Fund L.P., an accredited institutional investor with its investment manager headquartered in New York, New York.

11 Mar 2010

Great Point and Deerfield invest in BioSante Pharmaceuticals

BioSante Pharmaceuticals, Inc. today announced the closing of the sale, directly to funds affiliated with two institutional investors, of an aggregate of approximately 10.4 million shares of BioSante’s common stock and warrants to purchase up to approximately 5.2 million shares of its common stock, resulting in gross cash proceeds to BioSante of $18 million.

11 Mar 2010

Watson Pharmaceuticals resolves Actos patent litigation

Watson Pharmaceuticals, Inc, today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.

11 Mar 2010

Majority of nurse practitioners recommend dietary supplements for overall health and wellness

Eighty-five percent of nurse practitioners agree that one of the roles of healthcare professionals is to provide their patients with information about dietary supplements, according to new research from the "Life...supplemented" 2009 Healthcare Professionals (HCP) Impact Study.

11 Mar 2010

Regence acquires assets of Kinetix Living

As part of its continued focus on developing programs designed to meet employers' needs, Regence has acquired the assets of Kinetix Living Corp., a Seattle-based company that provides customized health and nutrition programs to corporate clients and individuals throughout the country.

11 Mar 2010

Nabi Biopharmaceuticals closes exclusive option and license agreement for NicVAX with GSK

Nabi Biopharmaceuticals announced today that the closing requirements set forth in the exclusive option and license agreement for NicVAX® (Nicotine Conjugate Vaccine), dated November 13, 2009 with GlaxoSmithKlineBiologicals S.A. have been met and the companies have closed the agreement.

11 Mar 2010

Regence Blueshield acquires Seattle-based health and wellness company

Maveron LLC, a Seattle-based venture capital firm focused on helping exceptional entrepreneurs build great consumer businesses, announced the asset acquisition of portfolio company Kinetix Living Corp. by Regence BlueShield of Washington. Terms of the transaction were not disclosed.

11 Mar 2010

Discovery Laboratories reports net loss of $6.1M for fourth-quarter 2009

Discovery Laboratories, Inc. today announces financial results for the fourth quarter ended December 31, 2009 and provides a business update.

10 Mar 2010

BioTime's fourth-quarter fiscal 2009 total quarterly revenue up 163%

BioTime, Inc. today reported financial results for the fourth quarter and fiscal year ended December 31, 2009 and provided an update on recent corporate developments.

10 Mar 2010

Study provides first formal analysis of comparative effectiveness research on new therapies

An analysis by researchers at the Keck School of Medicine of the University of Southern California has found that only 32 percent of medication studies published in top medical journals compare the effectiveness of existing treatments. These studies, known as comparative effectiveness studies, help doctors know which therapies work best and under what circumstances they are most effective.

10 Mar 2010

Health plan members who participate in health and fitness-related activities have lower healthcare costs

Employers are increasingly looking to workplace wellness programs to motivate employees to play an active role in improving their health, thereby reducing overall healthcare costs. Deepak N. Patel, MD, Mmed, senior clinical specialist for Discovery Vitality, will present new findings indicating that health plan members who participated in health and fitness-related activities within an incentive-based health insurance wellness program had significantly lower healthcare costs.

10 Mar 2010

Insulin resistance in Hepatitis C patients: Mostly in muscle and not in liver

We have known for several years that Hepatitis C, a common cause of liver cirrhosis and cancer, also makes people three to four times more likely to develop Type 2 diabetes.

10 Mar 2010

Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010

Helix BioPharma Corp. today announced financial results for the second quarter ended January 31, 2010.

10 Mar 2010

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the “Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus” trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

10 Mar 2010

Lonza acquires access to PCA technology patent portfolio

Odyssey Thera, Inc., announced today the signing of an agreement with Lonza to make Odyssey Thera's proprietary Protein-fragment Complementation Assay (PCA) technology, as part of compound profiling services, available to life science and drug discovery researchers.

10 Mar 2010

Study shows strawberries can provide immense health benefits

When it comes to eating healthy, most people know it's a good long-term choice, but what they may not know is that eating certain foods daily can provide immediate health benefits.

10 Mar 2010